PRF1 and neoplasm: More recently, Lutz et al. described notable anti-tumor efficacy of a B7-H3Xcd3 bispecific antibody in PAC, as evidenced by enhanced T-cell activation and secretion of IL-2, IFN-g, and perforin, which resulted in tumor cell lysis [90].